This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 8.74% and 1.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
by Zacks Equity Research
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cytokinetics (CYTK) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Cytokinetics (CYTK)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -26.67% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Cytokinetics (CYTK) Climb 48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 47.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Cytokinetics (CYTK)? Wall Street Analysts Think 37%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
New Strong Sell Stocks for August 27th
by Zacks Equity Research
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
New Strong Sell Stocks for August 18th
by Zacks Equity Research
CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -32.31% and -49.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?